Celldex Therapeutics, Inc.
Nasdaq · Healthcare · In Vitro & In Vivo Diagnostic Substances · Hampton, NJ
CLDX chart
What traders are saying about $CLDX
Latest postsCelldex Therapeutics, Inc. news
- Celldex Therapeutics, Inc. Estimates – NASDAQ:CLDX
TradingView ·
- Chronic Spontaneous Urticaria Clinical Trials Update 2026:
openPR.com ·
- Understanding Momentum Shifts in (CLDX)
Stock Traders Daily ·
- Celldex Therapeutics (CLDX) Stock Looks Rich After Shareholder Investigation
Yahoo Finance ·
- Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?
Yahoo Finance ·
- The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte
Yahoo Finance ·
- CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’
stocktwits.com ·
- Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses
marketbeat.com ·
- 4 Biotech Stocks With Key Clinical Readouts Expected This Fall
Yahoo Finance ·
- Celldex Shares Rise 8% as Barzolvolimab Meets Primary Endpoints in Two Phase 3 Trials
investorshub.advfn.com ·
- Celldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria Trials
Yahoo Finance ·
- Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
Yahoo Finance ·
Celldex Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $1.5M | $7.0M | $6.9M | $2.4M |
| Net income | -$258.8M | -$157.9M | -$141.4M | -$112.3M |
| Diluted EPS | $-3.90 | $-2.45 | $-2.92 | $-2.40 |
| Total assets (year end) | $583.0M | $792.3M | $465.6M | $352.7M |
| Cash and equivalents (year end) | $28.9M | $28.4M | $34.8M | $29.4M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Celldex Therapeutics, Inc.
- Ticker
- CLDX (Nasdaq)
- Industry
- In Vitro & In Vivo Diagnostic Substances
- Headquarters
- Hampton, NJ
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 744218
- Former names
- AVANT IMMUNOTHERAPEUTICS INC, T CELL SCIENCES INC
Frequently asked questions
What exchange is Celldex Therapeutics, Inc. listed on?
Celldex Therapeutics, Inc. trades on the Nasdaq under the ticker symbol CLDX.
What industry is Celldex Therapeutics, Inc. in?
Celldex Therapeutics, Inc. is classified by the SEC under "In Vitro & In Vivo Diagnostic Substances", part of the Healthcare sector on StockTweeting.
Where is Celldex Therapeutics, Inc. headquartered?
Celldex Therapeutics, Inc.'s business address on file with the SEC is in Hampton, NJ.
When does Celldex Therapeutics, Inc.'s fiscal year end?
Celldex Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Celldex Therapeutics, Inc. report?
Celldex Therapeutics, Inc. reported $1.5M in revenue for calendar year 2025, according to its SEC filings.